State Street’s Vor Biopharma VOR Stock Holding History

State Street’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.2M	Buy	2,616,336 +1,497,878	+134%	+$22.7M	﹤0.01%	1867
2026 Q1	$20M	Buy	1,118,458 +1,027,405	+1,128%	+$14.5M	﹤0.01%	2239
2025 Q4	$1.19M	Buy	91,053 +81,999	+906%	+$1.53M	﹤0.01%	3483
2025 Q3	$441K	Buy	9,054 +3,257	+56%	+$131K	﹤0.01%	3690
2025 Q2	$188K	Hold	5,797	–	–	﹤0.01%	3853
2025 Q1	$83.2K	Hold	5,797	–	–	﹤0.01%	4006
2024 Q4	$129K	Hold	5,797	–	–	﹤0.01%	3941
2024 Q3	$81.2K	Hold	5,797	–	–	﹤0.01%	4017
2024 Q2	$116K	Sell	5,797 -27,088	-82%	-$876K	﹤0.01%	3964
2024 Q1	$1.56M	Buy	32,885 +2,485	+8%	+$109K	﹤0.01%	3356
2023 Q4	$1.37M	Buy	30,400 +105	+0.3%	+$4.33K	﹤0.01%	3410
2023 Q3	$1.28M	Sell	30,295 -1,169	-4%	-$63.4K	﹤0.01%	3461
2023 Q2	$1.94M	Buy	31,464 +28,908	+1,131%	+$2.64M	﹤0.01%	3424
2023 Q1	$275K	Buy	2,556 +60	+2%	+$6.65K	﹤0.01%	3954
2022 Q4	$332K	Buy	2,496 +435	+21%	+$43K	﹤0.01%	3909
2022 Q3	$164K	Hold	2,061	–	–	﹤0.01%	4223
2022 Q2	$205K	Sell	2,061 -12,093	-85%	-$1.24M	﹤0.01%	4184
2022 Q1	$1.71M	Buy	14,154 +895	+7%	+$152K	﹤0.01%	3628
2021 Q4	$3.08M	Buy	13,259 +1,453	+12%	+$419K	﹤0.01%	3477
2021 Q3	$3.7M	Buy	11,806 +1,716	+17%	+$510K	﹤0.01%	3390
2021 Q2	$3.76M	Buy	10,090 +1,613	+19%	+$796K	﹤0.01%	3371
2021 Q1	$7.31M	Buy	+8,477	New	+$7.17M	﹤0.01%	2878

Other funds holding VOR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

State Street's VOR Position: Q2 2026 in Review

State Street increased its Vor Biopharma (VOR) stake by 134% in Q2 2026, buying an estimated $22.7M and bringing the position to 2,616,336 shares worth $48.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1867.

State Street first reported a position in VOR in Q1 2021 and has held it in 22 quarters since. 42 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

State Street held 2,616,336 shares of Vor Biopharma worth $48.2M as of Q2 2026.
State Street bought 1,497,878 Vor Biopharma shares in Q2 2026, an estimated $22.7M.
Vor Biopharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1867 holding.
State Street first reported a position in Vor Biopharma in Q1 2021 and has held it in 22 quarters since.
42 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.